中国民康医学
中國民康醫學
중국민강의학
Medical Journal of Chinese People's Health
2015年
19期
7-8,17
,共3页
万拉法新%阿米替林%糖尿病%情绪障碍
萬拉法新%阿米替林%糖尿病%情緒障礙
만랍법신%아미체림%당뇨병%정서장애
Venlafaxine%Amitriptyline%Diabetes mellitus%Mood disorder
目的:比较万拉法新与阿米替林治疗糖尿病伴发情绪障碍患者的疗效与安全性. 方法:40例伴情绪障碍糖尿病患者,随机分为万拉法新组和阿米替林组,每组各20例. 两组患者的疗程均为6周. 采用HAMD、HAMA表评定两组患者的临床疗效,TESS表评定患者的不良反应. 结果:治疗后1、2周末,万拉法新组患者评分下降较阿米替林组明显,4、6周末差异无显著性;万拉法新组患者的不良反应较阿米替林组少而轻. 结论:万拉法新治疗糖尿病伴情绪障碍疗效与阿米替林相当,但起效较快,安全性高,不良反应轻微.
目的:比較萬拉法新與阿米替林治療糖尿病伴髮情緒障礙患者的療效與安全性. 方法:40例伴情緒障礙糖尿病患者,隨機分為萬拉法新組和阿米替林組,每組各20例. 兩組患者的療程均為6週. 採用HAMD、HAMA錶評定兩組患者的臨床療效,TESS錶評定患者的不良反應. 結果:治療後1、2週末,萬拉法新組患者評分下降較阿米替林組明顯,4、6週末差異無顯著性;萬拉法新組患者的不良反應較阿米替林組少而輕. 結論:萬拉法新治療糖尿病伴情緒障礙療效與阿米替林相噹,但起效較快,安全性高,不良反應輕微.
목적:비교만랍법신여아미체림치료당뇨병반발정서장애환자적료효여안전성. 방법:40례반정서장애당뇨병환자,수궤분위만랍법신조화아미체림조,매조각20례. 량조환자적료정균위6주. 채용HAMD、HAMA표평정량조환자적림상료효,TESS표평정환자적불량반응. 결과:치료후1、2주말,만랍법신조환자평분하강교아미체림조명현,4、6주말차이무현저성;만랍법신조환자적불량반응교아미체림조소이경. 결론:만랍법신치료당뇨병반정서장애료효여아미체림상당,단기효교쾌,안전성고,불량반응경미.
Objective:To compare efficacy and safety of Venlafaxine and Amitriptyline in treatment of mood disorders in pa-tients with diabetes mellitus ( DM) . Methods:40 patients with DM were randomly assigned to Venlafaxine group and Amitriptyline group and treated for 6 weeks. The efficacy and side reactions were evaluated with Hamilton depression scale (HAMD), Hamilton Anxiety rating scale (HAMA) and treatment emergent symptom scale (TESS). Results: The scores of HAMD and HAMA of Ven-lafaxine group decreased more markedly than those of Amitriptyline group after the treatment in the first and second weekends. Howev-er, there were no significant differences in the 4th and 6th weekends. The side reactions were less and slighter in Venlafaxine group than those in Amitriptyline group. Conclusions:Venlafaxine has a similar efficacy with Amitriptyline in the treatment of the patients with DM, but the former arises faster, the safety is higher, and the side reactions are slighter.